AKD’s Top 3 Pharma Picks For 2026

Introduction

Pakistan’s pharmaceutical sector is entering 2026 with stronger earnings visibility, improving pricing flexibility, and rising focus on high-margin product categories. Companies with dominant brands, export diversification, chronic therapy exposure, and efficient manufacturing platforms are increasingly attracting investor attention as the sector transitions toward structurally higher profitability. Based on the latest corporate briefings and 2026 operational outlooks, three pharmaceutical companies continue to stand out within the Pakistan Stock Exchange: Highnoon Laboratories Limited, Haleon Pakistan Limited, and GlaxoSmithKline Pakistan.

3. GlaxoSmithKline Pakistan (GLAXO)

GlaxoSmithKline Pakistan ranks among the strongest pharmaceutical names for 2026 due to its structural margin recovery, dominant product portfolio, and strong liquidity position.

📢 Announcement: You can now access our services and similar analyses by opening an account with us via JS Global

Don't miss:

• Top 5 Analyst Questions From Lucky Core Industries (LCI) Corporate Briefing
• 5 Reasons Why MEBL Could Continue Rising Despite a Growth Slowdown
• AKD Predicts PSO Could Double From Here

Shift Toward High-Margin Products Is Reshaping Earnings

The company has significantly shifted its portfolio toward non-essential medicines, which now contribute nearly 52% of total sales. Its dermatology business has also become a major earnings driver, contributing 29% of total revenue. Key brands, including Dermovate, Betnovate, and Polyfax, helped the segment grow by 38% year-on-year.

API Price Decline Is Supporting Margins

GLAXO continues to benefit from lower international Active Pharmaceutical Ingredient prices. Amoxicillin prices, the key input for Augmentin and Amoxil, have declined by more than 40%, materially improving cost structures and supporting profitability. Corporate expectations indicate gross margins are likely to remain within the 36% to 38% range through 2027, compared to nearly 25% during late 2023.

Volume Recovery Strategy Is Now Underway

Following the pricing gains realized after deregulation, the company is now shifting focus toward volume-led growth. Management is targeting a 3% to 4% recovery in unit sales while continuing to strengthen market leadership across core pharmaceutical categories. Augmentin remains the country’s leading antibiotic brand in value, volume, and prescription share, while also becoming the first antibiotic brand in Pakistan to surpass PKR 11 billion in sales.

Strong Balance Sheet Supports Dividend Recovery

📢 Announcement: We're on WhatsApp – Join Us There! 

GLAXO remains completely debt-free and maintained approximately PKR 7 billion in cash as of September 2025. Low finance costs and promotional support from its global parent continue to support some of the strongest net profit margins within the pharmaceutical sector. Improved profitability and stronger cash generation have also supported the company’s return toward regular dividend payouts, including the reinstatement ofinterim dividends.

⚠️ This post reflects the author’s personal opinion and is for informational purposes only. It does not constitute financial advice. Investing involves risk and should be done independently. Read full disclaimer →